NASDAQ:GTXI - Nasdaq -
1.2
0 (0%)
The current stock price of GTXI is 1.2 null. In the past month the price increased by 4.35%. In the past year, price decreased by -93.78%.
GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx's lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.
Gtx
17 W Pontotoc Ave. Suite 100
MEMPHIS TN 38103
CEO: Marc S. Hanover
Phone: 901-523-9700
The current stock price of GTXI is 1.2 null.
The exchange symbol of Gtx is GTXI and it is listed on the Nasdaq exchange.
GTXI stock is listed on the Nasdaq exchange.
Gtx (GTXI) has a market capitalization of 28.86M null. This makes GTXI a Nano Cap stock.
Gtx (GTXI) has a support level at 1.19 and a resistance level at 1.21. Check the full technical report for a detailed analysis of GTXI support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GTXI does not pay a dividend.
Gtx (GTXI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.87).
ChartMill assigns a technical rating of 4 / 10 to GTXI. When comparing the yearly performance of all stocks, GTXI is a bad performer in the overall market: 96.42% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to GTXI. GTXI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months GTXI reported a non-GAAP Earnings per Share(EPS) of -1.8699999999999999. The EPS increased by 1.69% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -135.46% | ||
ROE | -147.3% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 60% to GTXI. The Buy consensus is the average rating of analysts ratings from 1 analysts.